Cirrhosis & Portal Hypertension — Cirrhosis and portal hypertension pathophysiology - Pathophysiology

SECTION 1

Historical Context & Motivation

The clinical entity we now recognize as cirrhosis has been observed for centuries, though the mechanistic understanding of how chronic hepatic injury leads to irreversible scarring and portal hemodynamic collapse is comparatively recent. Ancient Greek physicians described ascites and jaundice without understanding the underlying hepatic pathology, and it was not until the Renaissance and early modern era that anatomists began to correlate macroscopic liver changes with disease states. The recognition that the liver's unique dual blood supply—receiving both hepatic arterial and portal venous inflow—makes it vulnerable to a distinctive form of vascular derangement called portal hypertension represented a paradigm shift in hepatology. Understanding the pathophysiology of cirrhosis and portal hypertension remains foundational for healthcare students because these conditions underlie many of the most common and lethal gastrointestinal emergencies, including variceal hemorrhage, spontaneous bacterial peritonitis, and hepatorenal syndrome.

1819 • Laennec Coins "Cirrhosis"

René Laennec, better known for inventing the stethoscope, introduced the term cirrhose from the Greek kirrhos (tawny), describing the yellowish-brown nodular surface of the diseased liver at autopsy.

1906 • Eck Fistula & Portal Hemodynamics

Building on Nikolai Eck's 1877 portacaval shunt in dogs, researchers demonstrated that diverting portal blood away from the liver caused hepatic encephalopathy, establishing the physiological importance of first-pass hepatic metabolism and the concept of portosystemic shunting.

1945 • Hepatic Venous Pressure Gradient

The wedged hepatic venous pressure technique, later refined into the hepatic venous pressure gradient (HVPG), allowed clinicians to quantify portal pressure indirectly, transforming portal hypertension from a purely anatomical diagnosis into a measurable hemodynamic condition.

1980s • Stellate Cell Activation Paradigm

The discovery that quiescent hepatic stellate cells (Ito cells) transform into activated, collagen-producing myofibroblasts in response to hepatocyte injury provided the cellular basis for fibrogenesis and opened therapeutic targets for antifibrotic therapy.

2000s–Present • Non-invasive Fibrosis Assessment

Transient elastography (FibroScan), serum biomarker panels (FIB-4, APRI), and advanced MRI techniques now allow staging of fibrosis without liver biopsy, enabling earlier detection of cirrhosis and guiding screening for portal hypertension.

The central question that emerges from this history is: how does chronic hepatocyte injury, regardless of etiology, converge on a common final pathway of architectural distortion and vascular resistance that produces the clinical syndrome of portal hypertension and ultimately end-stage liver disease? Answering this question requires integrating cellular biology, hemodynamics, and clinical medicine—a synthesis that forms the core of this lesson.

SECTION 2

Core Principles & Definitions

Cirrhosis and portal hypertension are intimately linked but represent distinct pathological and hemodynamic entities. Cirrhosis is defined as diffuse hepatic fibrosis with conversion of normal liver architecture into structurally abnormal regenerative nodules. This architectural distortion is the anatomical substrate upon which portal hypertension develops. Portal hypertension, in turn, is a pathological increase in the portal venous pressure gradient, clinically significant when the hepatic venous pressure gradient (HVPG) exceeds 10 mmHg. The following core principles underpin the pathophysiology of both conditions.

Chronic Hepatocyte Injury & Necroinflammation

Regardless of etiology—viral hepatitis, alcohol, metabolic dysfunction-associated steatohepatitis (MASH), or autoimmune disease—persistent hepatocyte death triggers a wound-healing response. Necroinflammatory activity recruits Kupffer cells, macrophages, and lymphocytes that release pro-fibrogenic cytokines including TGF-β, PDGF, and TNF-α.

Hepatic Stellate Cell Activation & Fibrogenesis

Quiescent hepatic stellate cells in the space of Disse undergo phenotypic transformation into proliferative, contractile myofibroblasts. These activated cells deposit extracellular matrix (ECM) components—predominantly collagen types I and III—replacing the normal low-density matrix and capillarizing the sinusoids.

Sinusoidal Capillarization & Increased Resistance

Normal hepatic sinusoids are fenestrated, low-resistance vessels. Subendothelial collagen deposition obliterates fenestrae, creates a basement membrane, and narrows the sinusoidal lumen. This capillarization dramatically increases intrahepatic vascular resistance—the primary 'structural' component of portal hypertension.

Dynamic Vascular Tone Dysregulation

Beyond structural changes, an imbalance between intrahepatic vasoconstrictors (endothelin-1, thromboxane A₂) and vasodilators (nitric oxide, prostacyclin) increases sinusoidal tone. Paradoxically, the splanchnic circulation exhibits excessive vasodilation mediated by NO overproduction, increasing portal inflow and worsening hypertension.

Portosystemic Collateral Formation

Elevated portal pressure drives blood through collateral pathways connecting the portal and systemic venous circulations. These collaterals—esophageal, gastric, rectal, and umbilical—are thin-walled, prone to rupture, and clinically manifest as varices, caput medusae, and hemorrhoids.

✦

KEY TAKEAWAY

Think of the cirrhotic liver as a highway system undergoing permanent construction. Fibrosis narrows the lanes (increased vascular resistance), while regenerative nodules create detours that bypass functional liver tissue. Meanwhile, the feeder roads (splanchnic arteries) widen, pumping more traffic into the congested highway. The result is a traffic jam (portal hypertension) that forces vehicles onto dangerous side roads (portosystemic collaterals) never designed for heavy traffic.

SECTION 3

Visual Explanation — From Normal Lobule to Cirrhotic Architecture

Left: A normal hepatic lobule with a central vein (blue) at its center and portal triads (green circles) at the hexagonal periphery, connected by orderly sinusoidal channels (violet lines). Right: In cirrhosis, dense fibrous septa (yellow) encircle regenerative nodules (red ellipses), obliterating the normal lobular architecture and creating high-resistance vascular pathways.

The diagram above illustrates the fundamental architectural transformation that defines cirrhosis. In the normal liver, blood flows from the portal triads through fenestrated sinusoids to the central vein in a highly organized radial pattern that maximizes contact between plasma and hepatocytes. The sinusoidal endothelium lacks a conventional basement membrane, and the subendothelial space of Disse contains only sparse reticulin fibers, facilitating bidirectional exchange of macromolecules. In the cirrhotic liver, this orderly architecture is destroyed. Collagenous fibrous septa bridge portal triads and central veins, compressing and distorting hepatocyte plates into regenerative nodules that lack normal afferent and efferent vascular connections. The functional consequence is twofold: impaired hepatocellular function (because hepatocytes in nodules have reduced sinusoidal contact surface) and markedly increased intrahepatic vascular resistance that is the primary driver of portal hypertension.

SECTION 4

Hemodynamic Framework of Portal Hypertension

Portal hypertension can be understood through a modified application of Ohm's law adapted to fluid hemodynamics. In electrical circuits, voltage equals current times resistance; analogously, the pressure gradient across the portal venous system equals portal blood flow times vascular resistance. This relationship provides the conceptual scaffold for understanding both the structural and dynamic components of portal hypertension in cirrhosis.

PORTAL PRESSURE GRADIENT (OHM'S LAW ANALOGY)

ΔP = Q × R

Where ΔP = portal pressure gradient (mmHg), Q = portal venous blood flow (mL/min), and R = total resistance to portal flow. In cirrhosis, both Q (increased by splanchnic vasodilation) and R (increased by sinusoidal distortion and contractile stellate cells) are elevated, creating a 'double hit.'

POISEUILLE'S LAW — RESISTANCE DETERMINANTS

R = (8 × η × L) / (π × r⁴)

Where η = blood viscosity, L = vessel length, and r = vessel radius. Because resistance is inversely proportional to the fourth power of the radius, even modest narrowing of sinusoidal lumens by perisinusoidal collagen deposition produces a dramatic increase in intrahepatic resistance.

HEPATIC VENOUS PRESSURE GRADIENT (HVPG)

HVPG = WHVP − FHVP

Where WHVP = wedged hepatic venous pressure (a surrogate for portal pressure) and FHVP = free hepatic venous pressure (a surrogate for inferior vena cava pressure). Normal HVPG is 1–5 mmHg. Portal hypertension is defined as HVPG > 5 mmHg; it becomes clinically significant at ≥ 10 mmHg, when varices form, and high-risk at ≥ 12 mmHg, when variceal hemorrhage may occur.

The hemodynamic derangement in cirrhotic portal hypertension has two interacting components. The structural component (approximately 60–70% of increased resistance) arises from sinusoidal capillarization, fibrous septal compression, and regenerative nodule formation. The dynamic component (approximately 30–40%) results from increased contractile tone of activated hepatic stellate cells and vascular smooth muscle within the intrahepatic vasculature, driven by endothelin-1 and reduced intrahepatic nitric oxide (NO) bioavailability. Critically, the splanchnic circulation responds to portal hypertension with paradoxical NO-mediated arteriolar vasodilation, increasing portal inflow (Q in the equation above) and creating a hyperdynamic circulatory state that perpetuates and worsens the pressure gradient.

⚠

The NO Paradox

A central paradox of cirrhotic hemodynamics is the intrahepatic deficit of nitric oxide coexisting with splanchnic excess of nitric oxide. Inside the liver, endothelial NO synthase (eNOS) activity is reduced and NO is scavenged by reactive oxygen species, resulting in unopposed vasoconstriction. Outside the liver, bacterial translocation and shear stress upregulate splanchnic eNOS, producing excessive vasodilation. This mismatch is a therapeutic target: liver-directed NO donors and systemic vasoconstrictors (e.g., terlipressin, octreotide) address each limb respectively.

SECTION 5

Classification of Portal Hypertension & Complications

Portal hypertension is classified anatomically based on the site of increased resistance relative to the hepatic sinusoids. This classification is clinically important because it determines the pattern of complications and guides diagnostic and therapeutic strategy. Additionally, understanding the downstream complications of portal hypertension—from variceal bleeding to hepatorenal syndrome—requires appreciating how elevated portal pressure propagates pathological effects across multiple organ systems.

Classification	Site of Resistance	Common Causes	HVPG Relationship
Prehepatic	Portal or splenic vein (before sinusoids)	Portal vein thrombosis, splenic vein thrombosis	HVPG is normal (resistance is upstream of the measured sinusoidal bed)
Intrahepatic — Presinusoidal	Portal venules within the liver	Schistosomiasis, primary biliary cholangitis, sarcoidosis	HVPG may be normal or mildly elevated
Intrahepatic — Sinusoidal	Hepatic sinusoids	Cirrhosis (all causes), alcoholic hepatitis	HVPG elevated — the classic measurable form
Intrahepatic — Postsinusoidal	Central hepatic venules	Sinusoidal obstruction syndrome (veno-occlusive disease)	HVPG elevated
Posthepatic	Hepatic veins, IVC, or right heart	Budd-Chiari syndrome, right heart failure, constrictive pericarditis	FHVP elevated; HVPG may be normal (both WHVP and FHVP rise)

Anatomical Classification of Portal Hypertension

This flowchart illustrates the major complications arising from clinically significant portal hypertension (HVPG ≥ 10 mmHg), including variceal hemorrhage, ascites, hepatic encephalopathy, hepatorenal syndrome, and spontaneous bacterial peritonitis (SBP). The bottom panel summarizes the underlying hyperdynamic circulatory state.

A key concept in this section is the HVPG threshold model of complications. While portal hypertension is technically defined at HVPG > 5 mmHg, complications do not appear uniformly. Varices typically develop at HVPG ≥ 10 mmHg, variceal bleeding becomes a risk at ≥ 12 mmHg, and the progression of ascites and hepatorenal syndrome correlates with worsening hemodynamic derangement. Importantly, reducing HVPG below 12 mmHg or by > 20% from baseline with pharmacotherapy (nonselective beta-blockers such as propranolol or carvedilol) significantly reduces variceal bleeding risk—a finding with direct clinical implications for primary and secondary prophylaxis.

SECTION 6

Worked Example — Clinical Vignette & Hemodynamic Analysis

Consider the following clinical scenario and trace the pathophysiological mechanisms from etiology through complication.

Case: A 55-year-old man with a 20-year history of heavy alcohol use presents with new-onset abdominal distension, bilateral lower extremity edema, and confusion. Labs reveal albumin 2.4 g/dL, total bilirubin 4.8 mg/dL, INR 1.9, creatinine 1.8 mg/dL, and ammonia 95 μmol/L. Upper endoscopy reveals large esophageal varices with red wale marks. Hepatic catheterization shows WHVP = 24 mmHg and FHVP = 6 mmHg.

1
Step 1 — Identify Etiology & Pathogenesis

The patient has chronic heavy alcohol use, the leading cause of cirrhosis in many populations. Ethanol and its metabolite acetaldehyde cause direct hepatocyte injury, generate reactive oxygen species, and activate Kupffer cells. These cells release TGF-β, which transforms quiescent hepatic stellate cells into collagen-producing myofibroblasts. Over 20 years, progressive fibrosis has replaced normal lobular architecture with regenerative nodules encased in fibrous septa.

Etiology: Alcohol-related liver disease → cirrhosis via stellate cell-mediated fibrogenesis
2
Step 2 — Calculate the HVPG

Using the HVPG formula: HVPG = WHVP − FHVP = 24 mmHg − 6 mmHg = 18 mmHg. Normal HVPG is 1–5 mmHg. This value exceeds both the 10 mmHg threshold for clinically significant portal hypertension and the 12 mmHg threshold for variceal hemorrhage risk, consistent with severe portal hypertension.

HVPG = 18 mmHg → Severe portal hypertension (sinusoidal pattern)
3
Step 3 — Link HVPG to Varices

The HVPG of 18 mmHg well exceeds 12 mmHg. Elevated portal pressure drives blood retrograde through portosystemic collaterals, including the left gastric (coronary) vein to the esophageal venous plexus. These thin-walled submucosal veins dilate under the transmitted pressure. Red wale marks on endoscopy indicate areas of focal wall thinning with high rupture risk—this patient requires urgent variceal hemorrhage prophylaxis (band ligation or nonselective beta-blocker therapy).

Large varices with red wale marks = high bleeding risk; requires primary prophylaxis
4
Step 4 — Explain the Ascites & Edema

Portal hypertension causes splanchnic arteriolar vasodilation (NO-mediated), reducing effective arterial blood volume. Baroreceptor activation triggers the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system (SNS), and non-osmotic release of ADH (vasopressin), leading to avid sodium and water retention. Simultaneously, low serum albumin (2.4 g/dL) reduces plasma oncotic pressure. The combination of increased portal hydrostatic pressure, reduced oncotic pressure, and renal sodium/water retention produces transudative ascites (serum-ascites albumin gradient [SAAG] ≥ 1.1 g/dL) and peripheral edema.

Ascites mechanism: ↑ Portal hydrostatic pressure + ↓ Oncotic pressure + RAAS/SNS/ADH activation
5
Step 5 — Explain Encephalopathy & Renal Dysfunction

Portosystemic shunting allows gut-derived ammonia to bypass hepatic first-pass metabolism. Elevated serum ammonia (95 μmol/L) crosses the blood-brain barrier and is metabolized by astrocytes via glutamine synthetase. Osmotically active glutamine accumulates, causing astrocyte swelling, cerebral edema, and altered neurotransmission—manifesting as confusion (grade II hepatic encephalopathy). The elevated creatinine (1.8 mg/dL) in the setting of cirrhosis, ascites, and low mean arterial pressure raises concern for hepatorenal syndrome (HRS), where extreme splanchnic vasodilation causes compensatory renal vasoconstriction and falling GFR despite structurally normal kidneys.

Encephalopathy: shunting → ↑ ammonia → astrocyte swelling. Renal: splanchnic vasodilation → ↓ renal perfusion → HRS

SECTION 7

Compensated vs. Decompensated Cirrhosis

A clinically vital distinction in cirrhosis management is the transition from the compensated to the decompensated state. Compensated cirrhosis describes a patient whose liver, despite extensive fibrosis and architectural distortion, maintains sufficient synthetic and metabolic function to avoid the major clinical complications. Decompensated cirrhosis is defined by the first occurrence of a clinical complication—ascites, variceal hemorrhage, hepatic encephalopathy, or jaundice—and marks a dramatic shift in prognosis from a median survival of > 12 years to approximately 2 years without liver transplantation.

Feature	Compensated Cirrhosis	Decompensated Cirrhosis
Clinical presentation	Often asymptomatic or nonspecific fatigue; may have spider angiomata, palmar erythema	Ascites, variceal bleeding, hepatic encephalopathy, jaundice
HVPG	Typically 6–9 mmHg (portal hypertension present but subclinical)	Usually ≥ 10–12 mmHg
Hepatic synthetic function	Albumin > 3.5 g/dL; INR near normal; bilirubin normal	Albumin often < 3.0 g/dL; INR > 1.5; bilirubin elevated
Child-Pugh class	Typically A (5–6 points)	B (7–9 points) or C (10–15 points)
MELD score	Usually < 10	Often > 15; used for transplant prioritization
Median survival	> 12 years	≈ 2 years without transplantation
Annual transition rate	5–7% per year progress to decompensated	N/A (decompensation is generally irreversible)

Compensated vs. Decompensated Cirrhosis

✦

KEY TAKEAWAY

The compensated-to-decompensated transition in cirrhosis is analogous to a dam holding back a reservoir. In compensated cirrhosis, the dam (residual hepatic reserve) has cracks (fibrosis, rising portal pressure) but still contains the water. Decompensation is the point at which the dam fails—water breaches through as ascites, bleeding, or encephalopathy. Once the breach occurs, simply patching one hole rarely restores structural integrity; often only rebuilding the dam entirely (liver transplantation) can restore normal function.

SECTION 8

Connection to Advanced Concepts & Emerging Therapeutics

The pathophysiology of cirrhosis and portal hypertension intersects with several advanced topics that healthcare students will encounter in upper-level hepatology, transplant medicine, and critical care rotations. Understanding how foundational mechanisms connect to these advanced concepts provides a forward-looking perspective on current research and clinical decision-making.

Foundational Concept (This Lesson)	Advanced Extension
Stellate cell activation & fibrogenesis	Antifibrotic therapies targeting TGF-β signaling, LOXL2 inhibitors, and stellate cell senescence induction. Fibrosis regression has been demonstrated after SVR in hepatitis C—cirrhosis may be partially reversible.
HVPG measurement and thresholds	HVPG-guided pharmacotherapy (personalized beta-blocker dosing), baveno VII criteria for non-invasive risk stratification, and liver stiffness measurement (LSM ≥ 25 kPa as a surrogate for clinically significant portal hypertension).
Hyperdynamic circulation & splanchnic vasodilation	Acute-on-chronic liver failure (ACLF) — systemic inflammatory response syndrome superimposed on cirrhosis, causing multi-organ failure through immune dysregulation and circulatory collapse.
Portosystemic shunting & varices	Transjugular intrahepatic portosystemic shunt (TIPS) — an interventional radiology procedure creating a low-resistance channel between hepatic and portal veins to decompress portal hypertension, balanced against the risk of worsening hepatic encephalopathy.
Hepatorenal syndrome	Terlipressin (a vasopressin analog) reverses splanchnic vasodilation and improves renal perfusion. Recently FDA-approved (2022), it represents a pathophysiology-guided therapeutic advance bridging patients to transplantation.

From Foundational Pathophysiology to Advanced Hepatology

An especially exciting development is the concept of fibrosis regression. Historically, cirrhosis was considered irreversible. However, long-term studies of patients treated with direct-acting antiviral agents for hepatitis C have demonstrated histological regression of fibrosis and normalization of HVPG in a subset of patients who achieve sustained virologic response. Similarly, bariatric surgery-induced weight loss has been associated with MASH-related fibrosis regression. These observations have shifted the therapeutic paradigm: if the inciting injury is removed early enough, the balance between matrix deposition and matrix metalloproteinase (MMP)-mediated degradation may tip toward resolution. This reframing—from cirrhosis as a terminal destination to a potentially modifiable disease state—underscores the importance of early detection and etiology-specific treatment.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why the intrahepatic vasculature in cirrhosis exhibits increased vasoconstriction (decreased NO) while the splanchnic vasculature exhibits excessive vasodilation (increased NO). How does this 'NO paradox' contribute to the perpetuation of portal hypertension?

Show answer

In the cirrhotic liver, endothelial nitric oxide synthase (eNOS) activity is decreased due to inhibitory proteins (caveolin-1), reduced Akt-mediated eNOS phosphorylation, and scavenging of NO by superoxide radicals generated during oxidative stress. This creates a state of intrahepatic vasoconstriction that increases sinusoidal resistance—the dynamic component of portal hypertension. Conversely, in the splanchnic circulation, shear stress from portal hypertension and bacterial translocation from a gut with increased permeability upregulate eNOS and inducible NOS (iNOS), producing excessive NO. This vasodilation increases portal venous inflow (Q in the ΔP = Q × R equation), worsening the portal pressure gradient. The paradox thus creates a self-reinforcing cycle: increased intrahepatic resistance → portal hypertension → splanchnic vasodilation → increased portal inflow → further elevation of portal pressure.

Question 2: BASIC CALCULATION

A patient undergoes hepatic vein catheterization. The wedged hepatic venous pressure (WHVP) is 22 mmHg and the free hepatic venous pressure (FHVP) is 5 mmHg. Calculate the HVPG and state whether this patient is at risk for variceal hemorrhage.

Show answer

HVPG = WHVP − FHVP = 22 − 5 = 17 mmHg. The normal HVPG range is 1–5 mmHg, so this patient has portal hypertension. Because the HVPG exceeds 10 mmHg, the portal hypertension is clinically significant, meaning the patient is at risk for developing varices. Because it exceeds 12 mmHg, the patient is at specific risk for variceal hemorrhage. This HVPG of 17 mmHg indicates severe portal hypertension and warrants screening endoscopy for varices with initiation of primary prophylaxis (nonselective beta-blocker or endoscopic variceal ligation) if large varices or red wale marks are identified.

Question 3: INTERMEDIATE

A patient with cirrhosis and ascites has a serum albumin of 1.8 g/dL and ascitic fluid albumin of 0.3 g/dL. Calculate the serum-ascites albumin gradient (SAAG). Based on this value and the underlying diagnosis, explain the pathophysiological mechanism of ascites formation in this patient, integrating Starling forces, the RAAS, and the hyperdynamic circulatory state.

Show answer

SAAG = Serum albumin − Ascitic fluid albumin = 1.8 − 0.3 = 1.5 g/dL. A SAAG ≥ 1.1 g/dL indicates portal hypertension as the cause of ascites, which is consistent with cirrhosis. The mechanism involves multiple interacting forces. First, portal hypertension increases sinusoidal hydrostatic pressure, favoring fluid transudation into the space of Disse and then into the peritoneal cavity via the liver capsule. Second, hypoalbuminemia (1.8 g/dL) reduces plasma oncotic pressure, further favoring fluid extravasation per Starling's equation. Third, splanchnic NO-mediated vasodilation reduces effective arterial blood volume, triggering baroreceptor-mediated activation of RAAS, sympathetic nervous system, and ADH secretion. The resulting avid renal sodium and water retention expands plasma volume but preferentially redistributes to the peritoneal cavity due to the ongoing hydrostatic-oncotic imbalance. This creates a cycle where the kidney retains fluid that the circulation cannot effectively hold, perpetuating ascites formation.

Question 4: APPLIED

A 62-year-old woman with MASH-related cirrhosis is started on carvedilol for primary prophylaxis of variceal hemorrhage. After 4 weeks, a repeat HVPG measurement shows a decrease from 16 mmHg to 11 mmHg. Has the target HVPG response been achieved? Explain the dual mechanism by which nonselective beta-blockers reduce portal pressure in the context of the ΔP = Q × R relationship.

Show answer

The target for HVPG response in variceal hemorrhage prophylaxis is either a reduction below 12 mmHg or a ≥ 20% reduction from baseline. The baseline HVPG was 16 mmHg, and a 20% reduction would require achieving ≤ 12.8 mmHg. The measured 11 mmHg satisfies both criteria (it is below 12 mmHg, and the reduction is 5/16 = 31.25%, which exceeds 20%), so the target response has been achieved. Nonselective beta-blockers reduce portal pressure by acting on both components of the ΔP = Q × R equation. β₁-blockade reduces cardiac output, decreasing splanchnic blood flow and thus portal venous inflow (Q). β₂-blockade in the splanchnic arterioles causes unopposed α₁-adrenergic vasoconstriction, further reducing splanchnic blood flow. Carvedilol has the additional property of α₁-blockade, which reduces intrahepatic vascular resistance (R) by decreasing hepatic stellate cell contraction, potentially conferring an additional benefit over traditional nonselective beta-blockers like propranolol.

Question 5: CRITICAL THINKING

A patient with compensated cirrhosis from chronic hepatitis C achieves sustained virologic response (SVR) after direct-acting antiviral therapy. Over the next 3 years, liver stiffness measurement by transient elastography decreases from 28 kPa to 14 kPa. Discuss whether this patient can be considered 'cured' of cirrhosis. Address (a) the evidence for fibrosis regression, (b) the residual risk of hepatocellular carcinoma, and (c) the ongoing need for portal hypertension surveillance despite apparent improvement.

Show answer

(a) Evidence supports that fibrosis regression is possible after SVR in hepatitis C. Studies have demonstrated histological improvement, with some patients showing regression from Metavir F4 (cirrhosis) to F3 or even F2. A decrease in liver stiffness from 28 kPa to 14 kPa suggests significant reduction in hepatic fibrosis. However, liver stiffness measures total tissue stiffness, which includes inflammation, congestion, and fibrosis; improvement may partly reflect reduced necroinflammation rather than true collagen resorption. (b) Despite SVR and fibrosis regression, the patient retains an elevated risk of hepatocellular carcinoma (HCC) relative to the general population. Epigenetic changes, accumulated DNA damage during years of chronic inflammation, and residual architectural distortion create a persistent oncogenic milieu. Current guidelines (AASLD, EASL) recommend continued biannual HCC surveillance with ultrasound ± AFP for all patients who had cirrhosis at any point, regardless of SVR status. (c) Although HVPG may normalize in some SVR patients, portal hypertension can persist despite fibrosis regression if architectural distortion (regenerative nodules, vascular shunting) remains. Varices present before SVR may persist. The patient should continue endoscopic surveillance per guidelines until serial assessments confirm absence of varices and normalization of surrogate markers. This case illustrates that while 'curing' the etiology is a major advance, the downstream structural consequences of cirrhosis require ongoing clinical vigilance.

SUMMARY

Summary

Cirrhosis is the end result of chronic hepatic injury from any etiology, characterized by diffuse fibrosis and conversion of normal architecture into regenerative nodules. The key cellular mediator is the activated hepatic stellate cell, which deposits collagen types I and III in the space of Disse, causing sinusoidal capillarization and dramatically increasing intrahepatic vascular resistance. This structural change, combined with a dynamic vasoconstrictor-vasodilator imbalance (the NO paradox), elevates the hepatic venous pressure gradient (HVPG) beyond 5 mmHg, defining portal hypertension.

Portal hypertension becomes clinically significant at HVPG ≥ 10 mmHg and drives complications including variceal hemorrhage (risk at ≥ 12 mmHg), ascites (Starling force imbalance plus RAAS activation), hepatic encephalopathy (portosystemic shunting of ammonia), hepatorenal syndrome (renal vasoconstriction from splanchnic vasodilation), and spontaneous bacterial peritonitis. The transition from compensated to decompensated cirrhosis marks a critical prognostic inflection point, reducing median survival from > 12 years to approximately 2 years. Therapeutic strategies, including nonselective beta-blockers, variceal band ligation, and TIPS, are grounded in the hemodynamic principles of ΔP = Q × R and target both the structural and dynamic components of portal hypertension.